

## AZ Cotadutide Renal Trial

**Study location:** [BCDiabetes: 400 - 210 West Broadway, Vancouver V5Y 3W2](#)

**Principal Investigators** Dr. Tom Elliott

**Study coordinator & primary contact** Dr. Marla Inducil P: 604-628-7253 x 7011 :  
[minducil@bcdiabetes.ca](mailto:minducil@bcdiabetes.ca)

### Summary:

Cotadutide Renal Outcome Trial is A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled, and Open-label Comparator Study of Cotadutide in Participants Who Have Chronic Kidney Disease with Type 2 Diabetes Mellitus

### Eligible Participants include:

- Male or female aged 8-79 years
- eGFR 20-89 UACR > 5.7 mg/mmol
- A1c 6.5-12.5%
- BMI > 25
- On ACEi or ARB

### Treatment course and duration:

This is a randomised, double-blind, placebo-controlled, and open-label comparator study to evaluate the efficacy, safety, tolerability, and PK profile of cotadutide uptitrated from 50 to 100, 300, or 600 µg administered subcutaneously (SC) once daily over 26 weeks in participants who have CKD with T2DM (eGFR ≥ 20 and < 90 mL/min/1.73 m<sup>2</sup> and micro- or macroalbuminuria). Placebo will be matched to cotadutide. The open-label comparator, semaglutide, will be administered subcutaneously (SC) from 0.25 to 1.0 mg once weekly over 26 weeks. Cotadutide, placebo, and semaglutide will be administered using an injection pen device.

### Odds of receiving placebo:

The odds of receiving placebo are 1/5 (20%). The odds of receiving teplizumab are 3/5(60%). The odds of receiving semaglutide is 1/5 (20%)

### Other Notes:

CGM provided; visits every 2 weeks for 28 weeks

Short URL = <https://bit.ly/3IJAjT5>